Abstracts Archive - Page 1657 of 2425 - ACR Meeting Abstracts

Abstract Number: 2774 • 2015 ACR/ARHP Annual Meeting
Longterm Outcome of Patients Switched from Iv to Sc Formulation of Abatacept: A Monocentric Study
Rossella Reggia¹, Ilaria Cavazzana¹, Angela Tincani² and Franco Franceschini¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia, Brescia, Italy
Background/Purpose: Abatacept is a selective T cell costimulation modulator indicated for active Rheumatoid Arthritis (RA). Since August 2013, in Italy, the drug has also been…
Abstract Number: 2775 • 2015 ACR/ARHP Annual Meeting
What Factors Are Associated with Starting an Intravenous Vs. Sub-Cutaneous Biologic in Patients with RA?
Kaleb Michaud^1,2, Sofia Pedro² and Steven Peterson³, ¹Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Janssen Global Services, LLC, Malvern, PA
Background/Purpose: To characterize which factors are associated with RA patients' preferences for biologic administration: sub-cutaneous or intravenous.Methods: Using a large US observational cohort, the National…
Abstract Number: 2776 • 2015 ACR/ARHP Annual Meeting
Profiling Compounds in Human Primary Cell-Based Disease Models Guide Indication Selection
Jason Ptacek, Ellen L. Berg and Alison O'Mahony, BioSeek, a division of DiscoveRx Corp., South San Francisco, CA
Background/Purpose: In vitro co-cultures of human primary cells, including immune cells, fibroblasts, smooth muscle, keratinocytes, epithelial or endothelial cells were developed to capture the complexity…
Abstract Number: 2777 • 2015 ACR/ARHP Annual Meeting
Drug Retention Rates of Biologic Monotherapies for Patients with Rheumatoid Arthritis Receiving TNF Inhibiting Fusion Protein Agent and Antibody Agent; From Multicenter Registry in Japan
Hiroyuki Matsubara¹, Masatoshi Hayashi², Nobunori Takahashi³, Toshihisa Kojima³, Koji Funahashi³ and Naoki Ishiguro⁴, ¹Department of Orthopedic Surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ²Department of Orhtopedic Surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ³Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ⁴Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: In general, drug retention rate reflects the effectiveness and tolerability of the drug. TNF inhibitors include fusion protein agent such as etanercept (ETN) and…
Abstract Number: 2778 • 2015 ACR/ARHP Annual Meeting
Abatacept-Treated Rheumatoid Arthritis Patients Have Better Drug-Survival Rate When Abatacept Is the First or Second Line Biologic Agent with an Excellent Overall Safety Profile: A Single Center Experience
Irini Flouri¹, Argyro Repa², Antonis Fanouriakis², Nikolaos Kougkas², Ioannis Papalopoulos², Eleni Kampouraki², Dimitrios Boumpas³, Nestor Avgoustidis², George Bertsias² and Prodromos Sidiropoulos², ¹Rheumatology, Clinical Immunology, Allergy, University of Crete, Medical School, University Hospital, Heraklion, Greece, ²Rheumatology, Clinical Immunology, and Allergy, University of Crete, Medical School, University Hospital, Heraklion, Greece, ³Biomedical Research Foundation, Academy of Athens, Athens, Greece
Background/Purpose: Long-term prospective observational studies are complementary to controlled clinical trials in exploring the effectiveness and safety of biological therapies in rheumatoid arthritis (RA). We…
Abstract Number: 2779 • 2015 ACR/ARHP Annual Meeting
Better Drug Survival of Non-TNFi Compared to TNFi Biologics after Non-TNFi Failure in RA Patients: A Single Center Experience
Konstantinos Thomas, Christos Koutsianas, Argyro Lazarini, Christina Tsalapaki, Chrisoula Hatzara, Anna Kandili, Katerina Antonatou and Dimitrios Vassilopoulos, University of Athens Medical School, Clinical Immunology and Rheumatology Unit, 2nd Department of Medicine and Laboratory, Athens, Greece
Background/Purpose: There are sparse data in the literature regarding the drug survival of TNFi vs. non-TNFi biologics in rheumatoid arthritis (RA) patients who have already…
Abstract Number: 2780 • 2015 ACR/ARHP Annual Meeting
Relationship Between Immunogenicity, Hypersensitivity Reactions and Skin Tests Against Infliximab, Etanercept and Adalimumab in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
Firas Doghanji¹, Sebnem Ataman², Ali Erhan Ozdemirel², Recep Bülent Seckin¹, Ayse Peyman Yalcin¹ and Sevim Bavbek³, ¹Physical Medicine and Rehabilitation, Ankara University Faculty of Medicine, Ankara, Turkey, ²Rheumatology Department, Ankara University Faculty of Medicine, Ankara, Turkey, ³Immunology and Allergy, Ankara University Faculty of Medicine, Ankara, Turkey
Relationship between immunogenicity, hypersensitivity reactions and skin tests against Infliximab, Etanercept and Adalimumab in patients with rheumatoid arthritis and ankylosing spondylitis Background/Purpose: Anti-TNF drugs can…
Abstract Number: 2781 • 2015 ACR/ARHP Annual Meeting
Absence of Effects of Filgotinib on Erythrocytes, CD8+ and NK Cells in Rheumatoid Arthritis Patients Brings Further Evidence for the JAK1 Selectivity of Filgotinib
René Galien^1,2, Reginald Brys³, Annegret Van der Aa³, Pille Harrison³ and Chantal Tasset³, ¹Galapagos SASU, Romainville, France, ²102 Avenue Gaston Roussel, Galapagos SASU, Romainville, France, ³Galapagos NV, Mechelen, Belgium
Background/Purpose: The distinct role of JAK family members (JAK1, JAK2, JAK3 and TYK2) in signaling for cytokines and growth factors has established these kinases as…
Abstract Number: 2782 • 2015 ACR/ARHP Annual Meeting
Not Only 5 but Also 6 Weeks Intervals of Tocilizumab Infusion Induce Clinical Remission in Patients with Active Rheumatoid Arthritis
Hiroshi Uda¹, Koji Shigematsu², Yoshitaka Ishizaki² and Osamu Saiki^1,3, ¹Rheumatology, Higashiosaka City General Hospital, Higashiosaka, Japan, ²Orthopedics, Higashiosaka City General Hospital, Higashiosaka, Japan, ³Rheumatology, Shiraishi Hospital, Imabari, Japan
Background/Purpose: For active rheumatoid arthritis patients with inadequate response to synthetic disease modifying antirheumatic drugs (DMARDs), biologic agents are indicated. However, the cost of biologics,…
Abstract Number: 2783 • 2015 ACR/ARHP Annual Meeting
What Is the Rate of Primary and Secondary Failure of Anti-TNF in RA Patients? Data from a Rheumatoid Arthritis Cohort
Edward C. Keystone¹, Mohammad Movahedi^2,3, Angela Cesta², Xiuying Li², Sandra Couto², Emmanouil Rampakakis³, John S. Sampalis^3,4, Claire Bombardier^2,5,6 and OBRI Investigators, ¹The Rebecca MacDonald Centre For Arthritis, Mount Sinai Hospital, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ³JSS Medical Research, St-Laurent, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵University of Toronto, Department of Medicine (DOM) and Institute of Health Policy Management, and Evaluation (IHPME), Toronto, ON, Canada, ⁶Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Although the majority of RA patients respond to treatment with anti-TNF agents, some patients present with refractory disease (1ry failure) while others show some…
Abstract Number: 2784 • 2015 ACR/ARHP Annual Meeting
Faecal Levels of Calprotectin Are Increased in Patients with Primary Sjögren’s Syndrome and Correlates with Disease Activity
Thomas Mandl¹, Bodil Ohlsson² and Kristofer Andreasson³, ¹Dept of Rheumatology, Skåne University Hospital Malmö, Lund University, Malmo, Sweden, ²Dept of Internal Medicine, Skane University Hospital Malmo, Lund University, Sweden, Malmo, Sweden, ³Dept of Rheumatology, Skane University Hospital Lund, Lund University, Sweden, Lund, Sweden
Background/Purpose: FC is a validated biomarker differentiating inflammatory bowel disease from irritable bowel syndrome. We have evaluated faecal levels of calprotectin (FC) in patients with…
Abstract Number: 2785 • 2015 ACR/ARHP Annual Meeting
Association of Anti-Glutamate Receptor Subunit NR2 Antibody and Psychiatric Disorder in Patients with Primary Sjögren Syndrome
Yoshiyuki Arinuma^1,2, Yuko Sakuma³, Eisuke Ogawa², Tatsuhiko Wada⁴, Tatsuo Nagai², Sumiaki Tanaka² and Shunsei Hirohata², ¹Center for Autoimmune and Musculoskeletal Diseases, The Feinstein Institute for Medical Research, Manhasset, NY, ²Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ³Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ⁴Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: Sjögren syndrome (SjS) is one of the autoimmune disease characterized by the production of autoantibodies. Patients with SjS frequently observe psychiatric manifestation such as…
Abstract Number: 2786 • 2015 ACR/ARHP Annual Meeting
miR200b-5p: A Possible Predictor of Lymphoma Development in Sjögren’s Syndrome (SS)?
Efstathia K. Kapsogeorgou^1,2, Vasiliki C. Gourzi¹ and Athanasios G. Tzioufas¹, ¹Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, ²Pathophysiology, School of Medicine, National University of Athens, Greece, Athens, Greece
Background/Purpose: miR200b miRNAs (miR200b-3p and miR200b-5p) are critical regulators of the expression of oncogenes and tumour suppressor genes. Herein, we sought to investigate whether their…
Abstract Number: 2787 • 2015 ACR/ARHP Annual Meeting
Expression of Interferons Lambda in Salivary Glands of Patients with Sjögren’s Syndrome
Eirini Apostolou¹, Efstathia K. Kapsogeorgou¹, Orsia D. Konsta¹, Maria Ioanna Saridaki², Evangelos Andreakos² and Athanasios G. Tzioufas¹, ¹Pathophysiology, Faculty of Medicine, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece, ²Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation Academy of Athens, Athens, Greece
Background/Purpose: Type I and II interferons (IFNs) have been implicated in the pathophysiology of Sjögren’s Syndrome (SS). Recently a new family of IFNs, namely type…
Abstract Number: 2788 • 2015 ACR/ARHP Annual Meeting
DNA Microarray Analysis of Labial Salivary Glands in Patients with Sjögren’s Syndrome: Comparison with IgG4-Related Disease
Hiroyuki Takahashi¹, Hiroto Tsuboi¹, Mana Iizuka¹, Hiromitsu Asashima¹, Tomoya Hirota¹, Yuya Kondo¹, Isao Matsumoto¹, Takayuki Sumida¹, Seiji Nakamura², Sachiko Furukawa², Masafumi Moriyama³, Yuji Nakai⁴, Keiko Abe⁴ and Toshio Yoshihara⁵, ¹Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Faculty of Dental Science, Kyushu University, Fukuoka, Japan, ³Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Sciences, Faculty of Dental Science, Kyushu University, Fukuoka, Japan, ⁴Functional Food Science and Nutrigenomics, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan, ⁵Department of Otolaryngology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: The previous reports showed that DNA microarray in Sjögren’s syndrome (SS) identified the genes associated with mononuclear infiltrates such as immunoglobulin, human leukocyte antigen,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].